46 AVENUE DE LA GRANDE ARMEE, PARIS, I0
Rezurock Approved in the EU to Treat Chronic Graft-Vs-Host Disease
Venglustat Earns Breakthrough Therapy Designation in the US for Type 3 Gaucher Disease
The Board of Directors proposes the appointment of Christel Heydemann as an independent director
Resignation of Paul Hudson as a director on February 18, 2026
Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
Filing of the 2025 U.S. Form 20-F and French 'Document d’Enregistrement Universel' containing the Annual Financial Report
Rilzabrutinib designated breakthrough therapy in the US and orphan drug in Japan for the treatment of warm autoimmune hemolytic anemia
Belén Garijo to become Chief Executive Officer
Annual and Transition Report of Foreign Private Issuers
Registration Statement for Securities to be Offered to Employees
Tender Offer Statement by Third Party
Tender Offer Statement by Issuer
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Additional Information Statement
Contested Proxy Solicitation Materials
PRRN14A
Amended Schedule 13G - Ownership Report
Quarterly Holdings Report for Institutional Managers
Annual Report of Proxy Voting Record
Annual Report of Employee Stock Purchase
Iran Notice
Amended Tender Offer Statement by Third Party
S-8 POS
Free Writing Prospectus